Among 119 tested compounds, naringin was one of the promising compounds as an AChE, BChE, and BACE-1 blocker because, in the molecular docking study, naringin exhibited high binding affinity relative to donepezil and elenbecestat, the AD drugs [37]. This evidence concerns the gene BCHE and Alzheimer disease.